Cited by 249Escherichia coli research studiesUrinary Tract Infections ManagementBacterial Infections and Vaccines

Extraintestinal Pathogenic Escherichia coli , a Common Human Pathogen: Challenges for Vaccine Development and Progress in the Field

Open access
Poolman, Jan T., Wacker, Michael·2016·Journal of Infectious Diseases

Abstract

Extraintestinal pathogenic Escherichia coli (ExPEC) is the most common gram-negative bacterial pathogen in humans. ExPEC causes the vast majority of urinary tract infections (UTIs), is a leading cause of adult bacteremia, and is the second most common cause of neonatal meningitis. Increasing multidrug resistance among ExPEC strains constitutes a major obstacle to treatment and is implicated in increasing numbers of hospitalizations and deaths and increasing healthcare costs associated with ExPEC infections. An effective vaccine against ExPEC infection is urgently needed. The O antigen, a component of the surface lipopolysaccharide, has been identified as a promising vaccine target. With the availability of a novel bioconjugation technology it is expected that multivalent O antigen conjugate vaccines can be produced at industrial scale. Clinical proof of concept of a 4-valent O antigen conjugate vaccine is ongoing. An ExPEC vaccine effective against strains that are associated with major diseases and resistant to multiple drugs could be routinely delivered to individuals at risk of developing severe E. coli infection, such as elderly people, individuals undergoing abdominal surgery and prostatic biopsy procedures, and persons at risk of recurrent and/or complicated UTI.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/infdis/jiv429

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • There are no licensed vaccines against E. coli or group B S. agalactiae.

    “There are no licensed vaccines against E. coli or group B S. agalactiae, despite these two pathogens being the major causes of bacterial meningitis in neonates.”

    From Global etiology of bacterial meningitis: A systematic review and meta-analysis. (2018) · cites this paper as [14]

    The Abstract says that no prophylactic vaccine against extraintestinal pathogenic E. coli (ExPEC) exists, supporting the E. coli portion within that scope. The paper does not address whether a vaccine against group B S. agalactiae is licensed, so it does not support the full claim. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 48 references couldn’t be matched to a known paper.

Research works printed but not linked: 4

  1. [6]Vahlne G Serological typing of the colon bacteria, with special reference to the occurrence of B. coli in man under normal and pathological conditions, particularly in appendicitis. Acta Path Microbiol Scand 1945; 62: 1.
  2. [7]Sjostedt S Pathogenicity of certain serological types of B. coli: their mouse toxicity, hemolytic power, capacity for skin necrosis and resistance to phagocytosis and bactericidal faculties of human blood. Acta Path Microbiol Scand 1946; 63: 1.
  3. [22]Elixhauser A, Friedman B, Stranges E Septicemia in U.S. Hospitals, 2009. Statistical brief 122. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs Rockville, MD: Agency for Health Care Policy and Research, 2006 http://www.ncbi.nlm.nih.gov/books/NBK65391/ Accessed 27 January 2015. 22049570
  4. [27]Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations. The Review on Antimicrobial Resistance Chaired by Jim O'Neill, 2014 http://www.his.org.uk/files/4514/1829/6668/AMR_Review_Paper_-_Tackling_a_crisis_for_the_health_and_wealth_of_nations_1.pdf Accessed 26 December 2014.

Cited by

Sorted by citations

Authors
Poolman, J. T., & Wacker, M.
Affiliations
Janssen (Netherlands) (NL)
Corresponding author
Poolman, Jan T.
Venue
Journal of Infectious Diseases
Published
2015-09-02
Volume
213
Issue
1
Pages
6-13
ISSN
  • 0022-1899 (ISSN-L)
  • 1537-6613
OpenAlex
W2243816940
Cited by
246
References
48
Citations by year
2026: 20 · 2025: 25 · 2024: 31 · 2023: 29 · 2022: 30 · 2021: 21 · 2020: 27 · 2019: 26 · 2018: 15 · 2017: 11 · 2016: 11
FWCI
1.36
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • The Journal of Infectious Diseases (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Escherichia coli research studies
  • Health Sciences › Medicine › Epidemiology › Urinary Tract Infections Management
  • Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
Keywords
extraintestinal pathogenic Escherichia coli, vaccine development, lipopolysaccharide, urinary tract infection, bacteremia, neonatal meningitis, multidrug resistance, bioconjugation, multivalent vaccine, vaccine targets
MeSH terms
Escherichia coli, Escherichia coli Infections, Humans, Urinary Tract Infections, O Antigens, Escherichia coli Vaccines, Drug Resistance, Bacterial

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review